Bellevue Group Portfolio holdings
Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$7.11M |
| 2 |
Integra LifeSciences
IART
|
+$6.94M |
| 3 |
Cigna
CI
|
+$6.83M |
| 4 |
Alkermes
ALKS
|
+$5.7M |
| 5 |
IQVIA
IQV
|
+$5.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRX
Akorn Inc
AKRX
|
+$11.9M |
| 2 |
Centene
CNC
|
+$9.33M |
| 3 |
Incyte
INCY
|
+$8.09M |
| 4 |
Ligand Pharmaceuticals
LGND
|
+$6.18M |
| 5 |
ALR
Alere Inc
ALR
|
+$5.78M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.43% |
| 2 | Financials | 0.93% |
| 3 | Miscellaneous | 0.38% |
| 4 | Industrials | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $34M | 4.02% |
261,992
+10,612
| +4% | +$1.3M |
2016 Q1
5 quarters
|
|
2
Amgen
AMGN
$253B
| $28.2M | 3.33% |
163,728
+8,278
| +5% | +$1.35M |
2016 Q1
5 quarters
|
|
3
Medtronic
MDT
$129B
| $27.1M | 3.21% |
305,500
+63,000
| +26% | +$5.31M |
2016 Q1
5 quarters
|
|
4
UnitedHealth
UNH
$363B
| $23.9M | 2.83% |
129,040
+5,100
| +4% | +$894K |
2016 Q1
5 quarters
|
|
5
Elevance Health
ELV
$92.9B
| $23.2M | 2.74% |
123,347
+12,887
| +12% | +$2.32M |
2016 Q1
5 quarters
|
|
|
6
Edwards Lifesciences
EW
$60.8B
| $22.5M | 2.66% |
569,700
+194,700
| +52% | +$7.11M |
2016 Q1
5 quarters
|
|
7
Intuitive Surgical
ISRG
$152B
| $22.2M | 2.62% |
213,354
+16,029
| +8% | +$1.54M |
2016 Q1
5 quarters
|
|
8
Gilead Sciences
GILD
$208B
| $22.1M | 2.61% |
311,803
+21,375
| +7% | +$1.42M |
2016 Q1
5 quarters
|
|
9
Abbott
ABT
$186B
| $21.5M | 2.55% |
443,000
+37,500
| +9% | +$1.7M |
2016 Q1
5 quarters
|
|
10
Align Technology
ALGN
$11.8B
| $20.4M | 2.42% |
136,200
| – | – |
2017 Q1
1 quarter
|
|
11
Illumina
ILMN
$31.7B
| $18.8M | 2.23% |
111,502
+9,788
| +10% | +$1.69M |
2016 Q1
5 quarters
|
|
12
Boston Scientific
BSX
$64.1B
| $17.4M | 2.06% |
628,000
+56,000
| +10% | +$1.49M |
2016 Q1
5 quarters
|
|
13
Biogen
BIIB
$37B
| $16.7M | 1.97% |
61,500
+8,000
| +15% | +$2.12M |
2016 Q1
5 quarters
|
|
14
Jazz Pharmaceuticals
JAZZ
$15.4B
| $15.6M | 1.84% |
100,203
-6,397
| -6% | -$978K |
2016 Q1
5 quarters
|
|
|
15
Incyte
INCY
$24.8B
| $15.5M | 1.84% |
123,412
-63,538
| -34% | -$8.09M |
2016 Q1
5 quarters
|
|
16
Eli Lilly
LLY
$1.27T
| $14.9M | 1.76% |
181,073
+49,673
| +38% | +$4.05M |
2016 Q1
5 quarters
|
|
17
DELISTED
Walgreens Boots Alliance
WBA
| $14.6M | 1.72% |
185,872
+25,463
| +16% | +$2.1M |
2017 Q1
1 quarter
|
|
18
Regeneron Pharmaceuticals
REGN
$98.4B
| $13.8M | 1.63% |
28,100
-1,200
| -4% | -$525K |
2016 Q1
5 quarters
|
|
|
19
Centene
CNC
$34.8B
| $13.6M | 1.6% |
339,620
-247,060
| -42% | -$9.33M |
2016 Q1
5 quarters
|
|
20
Baxter International
BAX
$13.3B
| $12.5M | 1.47% |
206,000
+16,000
| +8% | +$909K |
2016 Q1
5 quarters
|
|
21
DELISTED
Hologic
HOLX
| $12.4M | 1.47% |
273,423
-69,067
| -20% | -$3.05M |
2016 Q1
5 quarters
|
|
22
Danaher
DHR
$163B
| $12.1M | 1.43% |
161,304
+32,712
| +25% | +$2.45M |
2016 Q4
2 quarters
|
|
|
ABMD
23
DELISTED
Abiomed Inc
ABMD
| $12M | 1.42% |
83,970
+20,300
| +32% | +$2.73M |
2016 Q2
4 quarters
|
|
|
24
Cigna
CI
$78.1B
| $11.9M | 1.41% |
75,500
+42,500
| +129% | +$6.83M |
2016 Q1
5 quarters
|
|
|
BCR
25
DELISTED
CR Bard Inc.
BCR
| $11.8M | 1.39% |
37,290
-11,140
| -23% | -$3.31M |
2016 Q1
5 quarters
|
|
Similar funds
Bellevue Group's Q2 2017 Portfolio in Review
As of Q2 2017, Bellevue Group held 143 positions worth $846M, up 13% from $750M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Bellevue Group deployed $37.1M of net new capital in Q2 2017, opening 11 new positions and adding to 56 existing holdings. Its largest new stake was IQVIA: 66,520 shares worth $5.95M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Centene, an estimated $9.33M trimmed.
- Bellevue Group's largest Q2 2017 buy was IQVIA: 66,520 shares worth $5.95M.
- Bellevue Group added most to Edwards Lifesciences in Q2 2017, an estimated $7.11M increase.
- Bellevue Group's biggest Q2 2017 reduction was Centene, cutting an estimated $9.33M.
- Bellevue Group fully exited Akorn Inc in Q2 2017, selling an estimated $11.9M.
- Bellevue Group's ten largest holdings make up 29% of its $846M portfolio in Q2 2017.
- Bellevue Group opened 11 new positions and closed 11 in Q2 2017.
- Bellevue Group's portfolio value rose 13% quarter-over-quarter to $846M.
Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.